Datopotamab price and where to buy

Datopotamab Deruxtecan (Dato-DXd) is still in the clinical research and approval stage, so it has not yet been fully launched globally. Since the drug was jointly developed by Daiichi Sankyo and AstraZeneca and uses advanced antibody conjugation technology (ADC), the price after launch is expected to be higher. According to the market pricing of similar ADC drugs, the price of dabrotuzumab may be more than tens of thousands of yuan per tube, and the specific price still needs to be officially announced.

In the U.S. market, dabrotuzumab has entered the FDA priority review process and is expected to be approved for marketing in the future. If the drug is officially approved, formal purchase channels in the United States will mainly include hospitals, pharmacies, and prescriptions from doctors. Often, patients can receive partial reimbursement through commercial insurance or special medical plans, but may still be required to pay higher out-of-pocket costs.

In China, dabrotuzumab has not yet been officially launched, but has been included in the priority review process. If domestic patients want to obtain this drug, they can pay attention to its approval progress with the National Medical Products Administration (NMPA). In addition, some patients may obtain it through overseas medical institutions or cross-border drug purchase services, such as regular pharmacies or medical institutions in Hong Kong. It should be noted that there are certain legal and quality risks involved in cross-border drug purchase. Patients are advised to consult a professional doctor or obtain drugs through formal channels.

For patients who wish to start medication earlier, some international multicenter clinical trials may offer the opportunity to use dabrotuzumab. If they meet the enrollment conditions for clinical trials, patients can apply to participate in the hospital or drug research institution and receive the drug treatment at low cost or even free of charge. However, clinical trials are still in the research stage, and there may be uncertainties in efficacy and safety. Therefore, patients need to fully understand the content of the trial and communicate with their doctor in detail before deciding whether to participate.

Reference: https://clinicaltrials.gov/